Want to join the conversation?
Diagnostic products maker $BDX's 1Q16 revenues grew 1.8%, which is in line with the prior guidance of 1-2% growth, reflecting solid underlying growth in Medical and Life Sciences segments. Adjusted EPS was $1.96, helped by solid underlying performance of the segments and earnings were ahead of the company's expectations.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?